

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Receives High Marks for Participation in BiotoChina Investor Conference

Wilmington, DE – October 26, 2017 – CureDM received high marks for innovation during a teleconference with BiotoChina, a Houston, TX based partnering organization. BiotoChina helps innovative healthcare companies from worldwide connect with capital, market and manufacturers in China. Through an online pitch, CEOs in the US connect with targeted Chinese investors and get direct feedback to help plan strategy in China. Every week, three carefully selected companies present to Chinese investors with English-Chinese interpretation.

The participants rated CureDM with 4.3 out of 5 stars with respect to the innovation and their level of interest. Following the presentation, CEO Loraine Upham was invited to a one-on-one Skype interview to share more in depth information about the CureDM project, and drug discovery and development in general in the US. Upham commented, “The level of interest in the development of novel treatments for type 2 diabetes is enormous. Recent reports about the health economics of diabetes, specifically in China, are staggering and speak directly to the need for something new that might stop the downward spiral of this disease process.”

CureDM is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications are being pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX